- Poster presentation
- Open Access
Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
© Clark et al. 2015
Published: 4 November 2015
HD IL-2 was FDA approved for advanced mRCC, but the data supporting its use dates to the 1990's. We designed the PROCLAIMSM registry, including retrospective and prospective cohorts, to study modern outcomes and interactions with prior or subsequent targeted therapies. We now report survival analysis from the Registry and the effect of prior TT therapy.
Inclusion criteria required patients receive at least one dose of IL-2. Survival for both cohorts (N=408) is current to March 16, 2015.
Updated March 16, 2015
Retrsopective Cohort (2007-2012)N=97, 11 sites
Prospective Cohort (2011-2015)N=311, 39 sites
Median follow-up, months
1,2,3 year survival rate, CP/PR
100%, 89%, 84%
100%, 85%, 79%
1,2,3 year survival rate, SD
89%, 69%, 61%
95%, 76%, n/d
20% (CR: 5%, PR: 15%)
16% (CR: 3%, PR: 13%)
mOS no prioir TT/prior TT
48.9 (n=82)/15.3 (n=15)
NR (n=266)/22.1 (n=45)
PROCLAIM data demonstrate that SD, previously grouped with the non-responders, has extended survival rates. TT prior to HD IL-2 therapy was associated with a lower mOS. These data support that HD IL-2 has favorable safety profile compared to data in the original package insert and remains an effective first line therapy for eligible patients with mRCC.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.